According to a document submitted to the U.S. Securities and Exchange Commission (SEC) on March 2, Beam Therapeutics Inc. and Bio Palette have jointly decided to terminate the licensing agreement signed by both parties on March 27, 2019.

According to a document submitted to the U.S. Securities and Exchange Commission (SEC) on March 2, Beam Therapeutics Inc. and Bio Palette have jointly decided to terminate the licensing agreement signed by both parties on March 27, 2019.

老虎证券2026/03/05 22:04

Show original

The termination of the agreement was reached through mutual negotiation between both parties, and the specific terms and subsequent arrangements were not disclosed in detail in the filing documents. This change marks the official end of the collaboration between the two companies in the field of gene editing therapies.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

PoolX: Earn new token airdrops

Lock your assets and earn 10%+ APR

Lock now!

According to a document submitted to the U.S. Securities and Exchange Commission (SEC) on March 2, Beam Therapeutics Inc. and Bio Palette have jointly decided to terminate the licensing agreement signed by both parties on March 27, 2019.

You may also like

Trending news

Crypto prices